Can I stop taking neratinib/neratinib after double-targeting?

Dual-target therapy refers to a treatment method that uses two or more types of targeted drugs simultaneously in the treatment of breast cancer. This treatment method can attack tumor cells more comprehensively, reduce the chance of recurrence and metastasis, and thus improve the treatment effect. However, dual-target therapy also has a greater impact on the body and may lead to adverse reactions such as physical weakness. Neratinib is an oral targeted drug targeting the HER2 protein. It is mainly used to treat HER2-positive breast cancer and is a tyrosine kinase inhibitor.

The function of neratinib is to inhibit the activity of HER2 protein, thereby blocking the proliferation and survival signals of cancer cells. In some cases, doctors may recommend that patients after dual-target therapy continue to take neratinib to further consolidate the treatment effect and reduce the risk of cancer recurrence. However, the need to continue taking neratinib after dual-target therapy should be determined on a case-by-case basis. First, the doctor may develop an individualized treatment plan for the patient based on factors such as the patient's condition, pathological analysis results, and treatment progress. Your doctor will evaluate whether you need to continue taking neratinib or other medications.

By performing regular physical exams, exams, and imaging evaluations, doctors can learn how their patients are doing with their treatments. If the disease is stable or well controlled, continued use of neratinib may not be necessary. However, if your condition shows signs of worsening, your doctor may recommend continuing neratinib or adjusting your treatment regimen. Neratinib may cause some adverse reactions, such as diarrhea, vomiting, fatigue, etc. If a patient experiences significant adverse reactions or is unable to tolerate neratinib, doctors may consider adjusting the treatment plan.